Skip to content

A clinical trial to study the impact of low dose radiation to the lungs in patients with moderate COVID Pneumonia.

Study of Impact of adding Low Dose Pulmonary Radiotherapy to Moderate COVID-19 pneumonia patients. - IMpaCt-RT

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/033912
Enrollment
22
Registered
2021-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: D- Radiation Therapy

Interventions

Intervention1: Low dose Radiation.: Arm A will receive 0.7 Gy single fraction radiation to bilateral lungs along with institutional protocol. Control Intervention1: No Radiation will be given only

Sponsors

All India Institute of Medical Sciences Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age >= 18 years 2) Patients with confirmed diagnosis of SARS-Cov2 infection by RT-PCR on nasopharyngeal swab and / or bronchoalveolar lavage (BAL) 3) Patients having MOHFW Moderate disease with SpO2 20 Breaths per minute on Room Air with fewer than 8 days of symptom onset and currently receiving standard medication for COVID-19 at appropriate doses. Covid-19 classification criteria led down by MOHFW, Govt. Of India (Appendix 1) 4) Suggestive picture finding for interstitial pneumonia on chest X-ray and / or chest CT (optional) 5) Ability to understand and sign informed consent. 6) Ability to acquire and maintain the set-up necessary for the delivery of radiotherapy treatment

Exclusion criteria

Exclusion criteria: 1) Patients with MOHFW defined severe disease. 2) Patients undergoing invasive mechanical ventilation. 3) Patients with active autoimmune systemic diseases. 4) Hemodynamically unstable patients. 5) Patients with a positive pregnancy test. 6) Impossibility to maintain the set-up necessary for radiotherapy treatment.

Design outcomes

Primary

MeasureTime frame
Primary objective: To evaluate change from moderate to severe grade of disease in both the group with NEWS-2 Timepoint: Time Frame Day 1, Day 3, Day 7, Day 14

Secondary

MeasureTime frame
Secondary objective: To evaluate the changes in a. Change in physiological parameters including oxygen levels (PaO2 / FiO2), b. Change in laboratory testing WBC, platelets ESR, D-dimer, LDH, Ferritin, IL-6, CRP. c. Change in CECT Thorax that will be performed on follow up at 7 day and 28 days from baseline. Timepoint: Day 1.7.28 amd 6 months

Countries

India

Contacts

Public ContactPritanjali singh

All India Institute of Medical Sciences Patna.

drpritanjalis@aiimspatna.org09334931395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 12, 2026